Foghorn Therapeutics Inc.

FHTX Healthcare Biotechnology

Foghorn Therapeutics Inc.’s revenue for fiscal 2025 (year ended December 2025) was $30.9 million, up 36.8% from fiscal 2024. In the quarter to June 2026, revenue grew 112.7%, EPS grew 64.3% and free cash flow grew 14.9%, each against the same quarter a year earlier.

1.85 0.04 −2.12%
Market cap
$112.2M
P/E
0.0×
Fwd P/E
−3.7×
Dividend yield
—
F-score
2/9
Altman Z
−4.46
Beneish M
n/a
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
Piotroski F-Score
3 2 2 3

+8 more TTM periods

ROE
81.90% 109.12% 96.45% 122.30%
ROA
(30.06%) (31.33%) (30.82%) (28.10%)
ROIC
0.00% 0.00% 0.00% 0.00%
Return on Tangible Assets
(53.39%) (60.08%) (70.47%) (66.97%)
Average Days of Receivables
0.00 0.00 0.00 0.00
Free Cash Flow per Share
(1.19) (1.26) (1.37) (1.41)
Free Cash Flow
(84.31) (87.40) (86.15) (88.88)
Capital Expenditures
(0.07) — (0.05) (0.53)
Other line items
Cash ROIC
(97.43%) (80.57%) (166.81%) (96.74%)
Accounts Receivable Turnover
0.00 0.00 0.00 0.00
Accounts Payable Turnover
0.00 0.00 0.00 0.00
Average Days of Payables
0.00 0.00 0.00 0.00
Tax Rate
0.00 0.00 0.00 0.00
Research and Development Expense of Revenue
214.57% 290.88% 276.51% 342.31%
Selling, General and Administrative Expense of Revenue
71.81% 95.28% 89.13% 110.56%
Share Based Compensation of Revenue
26.97% 35.75% 33.64% 43.40%
Operating CF/Net income
1.30 1.16 1.16 1.23
Depreciation/Fixed assets
0.30 0.73 0.73 0.01
Capex/Depreciation
(0.16) 0.00 (0.04) (5.19)
Revenue per Share
0.52 0.41 0.49 0.39
Operating CF per Share
(1.19) (1.26) (1.37) (1.40)
Capex per Share
0.00 0.00 0.00 (0.01)
Capex to Sales
0.00 0.00 0.00 0.02

Fold the line items

Columns are period end dates